Toxicology Excellence for Risk Assessment, Cincinnati, OH, USA.
Crit Rev Toxicol. 2013 Jul;43(6):467-92. doi: 10.3109/10408444.2013.807223.
Over the last dozen years, many national and international expert groups have considered specific improvements to risk assessment. Many of their stated recommendations are mutually supportive, but others appear conflicting, at least in an initial assessment. This review identifies areas of consensus and difference and recommends a practical, biology-centric course forward, which includes: (1) incorporating a clear problem formulation at the outset of the assessment with a level of complexity that is appropriate for informing the relevant risk management decision; (2) using toxicokinetics and toxicodynamic information to develop Chemical Specific Adjustment Factors (CSAF); (3) using mode of action (MOA) information and an understanding of the relevant biology as the key, central organizing principle for the risk assessment; (4) integrating MOA information into dose-response assessments using existing guidelines for non-cancer and cancer assessments; (5) using a tiered, iterative approach developed by the World Health Organization/International Programme on Chemical Safety (WHO/IPCS) as a scientifically robust, fit-for-purpose approach for risk assessment of combined exposures (chemical mixtures); and (6) applying all of this knowledge to enable interpretation of human biomonitoring data in a risk context. While scientifically based defaults will remain important and useful when data on CSAF or MOA to refine an assessment are absent or insufficient, assessments should always strive to use these data. The use of available 21st century knowledge of biological processes, clinical findings, chemical interactions, and dose-response at the molecular, cellular, organ and organism levels will minimize the need for extrapolation and reliance on default approaches.
在过去的十几年中,许多国家和国际专家组已经考虑对风险评估进行具体改进。他们提出的许多建议是相互支持的,但其他建议似乎存在冲突,至少在初步评估中是这样。本综述确定了共识和分歧的领域,并建议采取一种实用的、以生物学为中心的前进道路,其中包括:(1) 在评估开始时明确提出问题的表述,其复杂程度应适合为相关风险管理决策提供信息;(2) 使用毒代动力学和毒效动力学信息来制定化学特定调整因子 (CSAF);(3) 使用作用模式 (MOA) 信息和对相关生物学的理解作为风险评估的关键、核心组织原则;(4) 将 MOA 信息整合到剂量-反应评估中,使用现有的非癌症和癌症评估指南;(5) 使用世界卫生组织/国际化学品安全规划署 (WHO/IPCS) 开发的分层迭代方法作为一种科学上稳健、适合综合暴露 (化学混合物) 风险评估的方法;(6) 将所有这些知识应用于在风险背景下解释人体生物监测数据。虽然在缺乏或不足以完善评估的 CSAF 或 MOA 数据时,基于科学的默认值仍然很重要且有用,但评估应始终努力使用这些数据。在分子、细胞、器官和生物体水平上利用现有的 21 世纪生物学过程、临床发现、化学相互作用和剂量-反应知识,将最大限度地减少外推和依赖默认方法的需要。